← Sanofi SA overview
Sanofi SASAN.PA

Why is Sanofi SA (SAN.PA) moving?

Q3 2026
▲2▼2

Pipeline wins offset safety setbacks and rising competition

  • New drug approvals and strong Q2 results Sanofi won FDA approval for subcutaneous Sarclisa Escena and EU approval for MenQuadfi in infants. Q2 sales rose 17.8% with raised guidance, and new drug sales grew 48.3%, supporting the growth story.

    These approvals and financial results are new positive developments that drove investor optimism.

  • Dupixent growth and expanded Regeneron alliance Dupixent continued to grow, and Sanofi expanded its antibody alliance with Regeneron. Nexviazyme also succeeded in phase 3 trials, adding to the pipeline of future growth drivers.

    Dupixent's ongoing growth and new partnership expansion are key positive drivers for future revenue.

  • Safety setbacks halt key programs Sanofi halted amlitelimab for atopic dermatitis and permanently stopped its infant RSV vaccine trial after a death. These safety issues raise concerns about pipeline reliability and future revenue.

    These setbacks are new negative events that weighed on sentiment and future growth prospects.

  • Intensifying competition threatens key products Competition increased from AbbVie, Moderna, Novartis, and AstraZeneca, putting pressure on Sanofi's key products. The Cheplapharm deal simplifies the portfolio but removes steady revenue.

    Rising competition and portfolio simplification are new negative factors affecting Sanofi's market position.

August 2026
▲2▼2

Sanofi's mixed month: pipeline wins, safety setback, rising competition

  • EU approval for MenQuadfi in infants Sanofi won EU approval for MenQuadfi in infants, expanding its meningitis vaccine to a younger age group. This opens a new market and supports future vaccine sales growth.

    New approval expands Sanofi's vaccine franchise and revenue potential.

  • Novavax partnership advances with Phase 3 combo study Sanofi advanced its Novavax partnership by starting a Phase 3 study of a combined COVID/flu vaccine. Success could simplify vaccination and strengthen Sanofi's position in the respiratory vaccine market.

    Shows progress in a key partnership that could yield a differentiated vaccine.

  • Infant RSV vaccine trial halted after death Sanofi permanently halted its infant RSV vaccine trial after an infant death. This removes a potential vaccine from the pipeline and raises safety concerns, weighing on sentiment.

    Major safety setback that eliminates a pipeline asset and damages confidence.

  • Rising competition from AbbVie and Moderna AbbVie is targeting a Dupixent rival, and Moderna launched the first mRNA flu shot. These competitive threats could pressure Sanofi's key products and future growth.

    Competitive landscape intensifies, posing risks to Sanofi's market share.

Latest
▲2▼2

Sanofi's pipeline setbacks and buyback shape mixed outlook

  • Amlitelimab discontinued for atopic dermatitis Sanofi stopped developing amlitelimab for atopic dermatitis after a pipeline review found it was no better than current treatments. This removes a key future immunology drug, which can lower investor expectations for growth and weigh on the stock price.

    This is a major pipeline failure that directly affects Sanofi's future revenue prospects.

  • Advertising watchdog questions Dupixent claims The National Advertising Division recommended Sanofi modify or stop some Dupixent TV and prescriber claims about long-lasting clearer skin and fast itch relief. This could limit marketing and slow sales of Sanofi's biggest drug, a negative for the stock.

    Regulatory scrutiny of Dupixent marketing could hurt sales of Sanofi's top revenue driver.

  • New Phase 1 trial for oral STAT6 degrader Sanofi began a Phase 1 trial of an oral STAT6 degrader for type 2 inflammatory diseases, triggering a $10 million milestone to partner Nurix. This early-stage asset shows pipeline progress and could become a future growth driver, supporting the stock.

    It demonstrates continued pipeline advancement despite the amlitelimab setback.

  • High dividend yield and buyback support valuation Sanofi offers a 5.6% dividend yield and completed a €1 billion buyback, with total shareholder yield near 11%. Dupixent sales grew 31% and the stock trades at a low forward P/E of 9, making it attractive to income and value investors.

    These capital returns and cheap valuation provide a floor for the stock price.

September 2026
▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

▲2▼2

Sanofi expands infant vaccine reach but faces pipeline and competition setbacks

  • EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

    This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

  • Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

    This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

  • Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

    This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

  • Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

    These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

July 2026
▲3▼1

Sanofi Q2 Beat and New Approvals Offset Pipeline Setback

  • FDA approves subcutaneous Sarclisa Escena The FDA approved Sarclisa Escena, the first on-body injector cancer treatment, offering patients a more convenient option and expanding Sanofi's oncology portfolio. This approval supports future revenue growth and boosts investor confidence.

    This is a new regulatory approval that directly supports Sanofi's growth outlook.

  • Q2 results beat expectations, guidance raised Sanofi reported Q2 sales up 17.8%, raised full-year guidance, and saw Dupixent sales surge 37.6% to €5.2bn. Partner Regeneron also posted a strong quarter, reinforcing confidence in Sanofi's growth trajectory.

    Strong quarterly results and raised guidance are key positive drivers for the stock.

  • Nexviazyme meets all phase 3 endpoints Nexviazyme met all phase 3 endpoints in infant Pompe disease, potentially expanding its label and addressing a serious unmet need. This positive trial outcome supports future sales growth and strengthens Sanofi's rare disease franchise.

    A successful phase 3 trial is a new positive catalyst for Sanofi's pipeline.

  • Sanofi halts amlitelimab for atopic dermatitis Sanofi halted development of amlitelimab for atopic dermatitis due to insufficient efficacy and safety, removing a much-anticipated growth driver. This setback weighs on sentiment and raises questions about the pipeline's near-term potential.

    This pipeline failure is a significant negative event that impacts future growth prospects.

▲3▼1

Sanofi raises outlook on Dupixent surge, but pipeline setback weighs

  • Q2 earnings beat and raised 2026 guidance Sanofi reported Q2 sales up 17.8% and raised its 2026 outlook, with Dupixent sales jumping 37.6% to €5.2 billion. This strong performance and confident guidance signal accelerating growth, which should lift investor confidence and support a higher share price.

    This is the most significant new event, directly showing Sanofi's financial health and future prospects.

  • Amlitelimab development halted for atopic dermatitis Sanofi discontinued amlitelimab for moderate-to-severe atopic dermatitis, a key pipeline candidate, due to insufficient efficacy and safety data. This removes a potential growth driver and may hurt sentiment, as investors had high hopes for the drug in a large market.

    This is a major pipeline setback that could negatively impact future revenue expectations.

  • Dupixent partner Regeneron beats estimates Regeneron's strong quarterly results, driven by Dupixent sales up 38% to $6 billion, confirm robust demand for Sanofi's top-selling drug. As Sanofi records these sales, the beat reinforces confidence in Dupixent's growth trajectory and Sanofi's earnings power.

    This provides independent validation of Dupixent's blockbuster performance, a key value driver for Sanofi.

  • Aqemia AI collaboration expands with new target Sanofi expanded its AI-driven drug discovery partnership with Aqemia, nominating a new target and potentially paying up to $140 million in milestones. This strengthens Sanofi's early-stage pipeline and shows commitment to innovative technologies, which could yield future blockbuster drugs.

    This highlights Sanofi's investment in cutting-edge R&D, supporting long-term growth prospects.

▲3▼1

Sanofi pipeline wins and FDA nod offset cautious analyst view

  • FDA approves Sarclisa Escena on-body injector The FDA approved subcutaneous Sarclisa Escena for all multiple myeloma uses, the first anticancer treatment given via on-body injector. It cuts treatment time and infusion reactions, which can lift sales and strengthen Sanofi's cancer franchise.

    This is a new regulatory approval that expands a key product's use and could drive future revenue.

  • Nexviazyme hits all goals in infant Pompe disease trial Sanofi's Nexviazyme met all endpoints in a phase 3 study for infants with infantile-onset Pompe disease, supporting a US label extension filing later in 2026. Success in a rare disease with few options adds a new growth driver.

    Positive late-stage trial data for an existing drug opens a new patient population and revenue stream.

  • WAYRILZ positioned in fast-growing AIHA market A market report projects 14.4% annual growth for warm autoimmune hemolytic anemia treatments through 2036, with no approved therapies yet. Sanofi's WAYRILZ is a key late-stage candidate, giving it a large untapped opportunity if approved.

    Highlights a new market opportunity for a Sanofi pipeline drug, supporting long-term growth prospects.

  • UBS cautious on Sanofi within favored pharma sector UBS likes European pharma as a safer bet than AI but is more cautious on Sanofi, preferring AstraZeneca and Roche. This relative caution may steer some investor money away from Sanofi shares, limiting upside versus peers.

    Analyst preference can influence capital flows and relative stock performance.

Q2 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

June 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.